Timing of Pre-operative Anti-VEGF for Vitrectomy in Proliferative Diabetic Retinopathy
- 29 December 2025
- journal article
- Published by Elsevier in Ophthalmology Retina
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82471085)
- State Key Laboratory of Ophthalmology (2025QZLH01)
This publication has 27 references indexed in Scilit:
- Anti-VEGF Injections vs. Panretinal Photocoagulation Laser Therapy for Proliferative Diabetic RetinopathyOphthalmology Retina, 2024
- Anti-VEGF crunch syndrome in proliferative diabetic retinopathy: A reviewSurvey of Ophthalmology, 2021
- Preoperative Bevacizumab Administration in Proliferative Diabetic Retinopathy Patients Undergoing Vitrectomy: A Randomized and Controlled Trial Comparing Interval VariationAmerican Journal of Ophthalmology, 2018
- Practical recommendations for reportingFine‐Gray model analyses for competing risk dataStatistics in Medicine, 2017
- Preoperative Intravitreal Bevacizumab Use as an Adjuvant to Diabetic Vitrectomy: Histopathologic Findings and Clinical ImplicationsOphthalmology, 2011
- Intravitreal bevacizumab for surgical treatment of severe proliferative diabetic retinopathyGraefe's Archive for Clinical and Experimental Ophthalmology, 2010
- Composite End Points in Randomized TrialsJAMA, 2010
- Injection of intravitreal bevacizumab (Avastin) as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy (PDR)Graefe's Archive for Clinical and Experimental Ophthalmology, 2008
- USE OF INTRAVITREAL BEVACIZUMAB AS A PREOPERATIVE ADJUNCT FOR TRACTIONAL RETINAL DETACHMENT REPAIR IN SEVERE PROLIFERATIVE DIABETIC RETINOPATHYRetina, 2006
- Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survivalDevelopmental Biology, 2003